BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2011 Financial Results on August 9, 2011

Aug 02, 2011, 08:00 ET from BioSpecifics Technologies Corp.

LYNBROOK, N.Y., Aug. 2, 2011 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced today that it will host a conference call and live audio webcast at 8:30am EDT on Tuesday, August 9, 2011 to report its second quarter 2011 financial results and corporate highlights.

The Company will be hosting a conference call to discuss these financial results and provide a corporate update. In order to participate, please dial 800-860-2442 (domestic) or 412-858-4600 (international). The live webcast can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at, or you may use the link:

A replay of the call will be available one hour after the conference ends on August 9, 2011 until 9:00am EDT on August 19, 2011. To access the replay, please dial 877-344-7529 (domestic) or 412-317-0088 (international) and reference the access code 10002978. The archived webcast will be available for 90 days in the Investor Relations section of the BioSpecifics' website at

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications, three of which include: Dupuytren's contracture, Peyronie's disease, and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. markets XIAFLEX® in the U.S. for the treatment of Dupuytren's contracture. Pfizer, Inc. is responsible for marketing XIAPEX® in Europe and has announced European regulatory approval and commenced sales in the United Kingdom, Germany, Denmark, Sweden, Finland, Norway, Austria and Switzerland. Asahi Kasei Pharma Corporation is responsible for marketing XIAFLEX® in Japan. More information about the Company may be found on its website at

SOURCE BioSpecifics Technologies Corp.